The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | FIGHT-202: pemigatinib in CCA
Ghassan K. Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the updated results from the FIGHT-202 trial (NCT02924376): a Phase II trial investigating the efficacy and safety of the FGFR inhibitor pemigatinib in patients with cholangiocarcinoma (CCA) and FGFR2 fusion. Pemigatinib improved patient outcomes; the overall response rate (ORR) of patients was 37% and the median overall survival (mOS) of responders was 30.1 months, compared to 13.7 months for non-responders. Adverse events were tolerable. The FIGHT-202 trial has led to the approval of pemigatinib for the treatment of CCA in patients with FGFR2 fusion by the FDA. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
